AI assistant
Niagen Bioscience, Inc. — Director's Dealing 2012
Feb 14, 2012
32418_dirs_2012-02-14_146b3493-622b-4136-91b4-81fc3bf37b0d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ChromaDex Corp. (CDXC.OB)
CIK: 0001386570
Period of Report: 2012-02-10
Reporting Person: Brauser Michael (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2012-02-10 | Common Stock | P | 200000 | $0.75 | Acquired | 2005714 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 1860712 | Indirect |
Footnotes
F1: Direct beneficial ownership includes 1,805,714 shares of common stock held by Michael & Betsy Brauser TBE.
F2: Indirect beneficial ownership includes: (i) 314,285 Shares held by Grander Holdings, Inc. 401K Profit Sharing Plan of which the Reporting Person is a trustee; (ii) 342,857 Shares held by the Brauser 2010 GRAT of which the Reporting Person is a trustee; (iii) 846,428 Shares held by BMB Holdings, LLLP of which the Reporting Person is the manager of its general partner; and (iv) 357,142 Shares held by Betsy Brauser Third Amended Trust Agreement beneficially owned by the Reporting Person's spouse which are disclaimed by him.